Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects

NCT ID: NCT01764425

Last Updated: 2013-07-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2013-02-28

Brief Summary

Clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjects

Detailed Description

• A phase I, randomized, double-blind, placebo-controlled, dose escalating study of P7435 to determine the safety, tolerability, pharmacokinetics, food effect and pharmacodynamics of single and multiple ascending doses of P7435.
• Subjects participating will be either healthy subjects or healthy overweight and/or obese subjects. In this study, overweight/obese are defined as subjects having a BMI of 23 kg/m2 and above.
• The study will be conducted in 3 parts as follows: Part A will consist of the Single Ascending Dose (SAD) study, Part B will consist of the Multiple Ascending Dose (MAD) study and Part C will consist of the Food Effect study.

Conditions

Healthy, Overweight and/or Obese Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

P7435

Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results

Group Type: ACTIVE_COMPARATOR

P7435

Intervention Type: DRUG

It is oral DGATI inhibitor with potential in dyslipidemia and T2DM

Placebo

Placebo tablets for oral administration

Group Type: PLACEBO_COMPARATOR

P7435

Intervention Type: DRUG

It is oral DGATI inhibitor with potential in dyslipidemia and T2DM

Interventions

P7435

It is oral DGATI inhibitor with potential in dyslipidemia and T2DM

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Willingness and are able to provide a written informed consent to participate in the study.
• Healthy adult male subjects aged between 18 and 45 (both inclusive) years old
• BMI between 19 and 23 kg/m2. Overweight (BMI between 23 and 25kg/m2) and/or obese (BMI between 25 and 35 kg/m2) but otherwise healthy subjects in PartB .
• Healthy as determined by the investigator
• Smoking less than 10 cigarettes per day and able to refrain from smoking during confinement.
• Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, coke, chocolate, "power drinks") and grapefruit juice to admission.

Exclusion Criteria

• Employees of the sponsor or clinical sites.
• Female subjects.
• No past or current serious diseases of any organ will be allowed. Exceptions may be non-malignant skin diseases, childhood asthma and other conditions as per the Investigator's discretion and discussed with the Sponsor a priori. History of significant gastrointestinal disease or other significant diseases including cardiac, renal or liver impairment.
• History of sleep apnea, irregular sleep/wake cycle or working in night shifts.
• Acute disease state
• History of hypo/hyperthyroidism or repeated abnormal TSH values at screening or obesity of endocrine origin.
• History of alcoholism for more than 2 years
• Positive serology for human immunodeficiency virus (HIV-1/2) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.
• Positive findings in urine drug screen / alcohol breath test.
• Participation in another clinical trial within 90 days of the first drug administration.
• Intake of more than 8-10 cups of coffee and/or tea per day and consumption of methyl xanthine-containing beverages (tea, coffee, cola drinks, chocolate) within 48 hours prior to study.
• Donation of blood (i.e. 350 ml) within 90 days before Day -1 of the first treatment period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Piramal Enterprises Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr Madhavi Latha Kodru

Role: PRINCIPAL_INVESTIGATOR

Dr Dharmesh Domadia

Role: PRINCIPAL_INVESTIGATOR

Locations

Piramal Clinical Research

Hyderabad, Andhra Pradesh, India

Veeda Clinical Research

Ahmedabad, Gujarat, India

Countries

India

Other Identifiers

P7435/66/11

Identifier Type: -

Identifier Source: org_study_id